Pharmaceutical Executive June 1, 2023
Bloomberg Intelligence survey credits increased medication access for potential spike.
According to a report by Bloomberg Intelligence, global obesity medication sales could reach $44 billion by 2030, up from $2.5 billion in 2022. Reportedly, analysts believe this will be the result of increased supply, growing demand, and further product innovation.
The organization also credits Novo Nordisk’s Wegovy and Eli Lilly’s tirzepatide with beginning the trend in an out-of-pocket market.
“Unprecedented demand in obesity coupled...